ABSTRACT
INTRODUCTION
Following the success of cisplatin as an anticancer agent, new interest raised on the design and development of new metal based antitumor agents 1, 2] . Within this frame Keppler and coworkers prepared and characterized a series of antitumor ruthenium(Ill) complexes, of which ICR (imidazolium bisimidazole tetrachloro ruthenate(III)) is probably the most representative [1] . Later on, Alessio and Sava developed NAMI A, a compound structurally related to ICR, that has recently entered phase clinical trials [3] . The biological evaluation of these innovative metal complexes has clearly pointed out that the mechanism of action of ruthenium compounds is substantially different from that of platinum complexes. Generally the direct cytotoxic effects of ruthenium compounds are much lower than those produced by equimolar amounts of cisplatin while the antimetastatic effects are more pronounced [3] . Also the direct DNA damaging effects are of much lower intensity [4] . In this context it is of interest to evaluate the biological effects of isostructural metal complexes, obtained by simple replacement of the central metal ion. The comparative analysis of the pharmacological profiles provides information on the specific role ofthe metal. Ruthenium(Ill) complexes may be easily mimicked by rhodium(Ill) complexes and iridium(Ill) complexes. Some studies already appeared on the rhodium(Ill) analogue of ICR [5] ; the iridium(lII) analogue of ICR-IRIM-has been recently synthesized by Mura [6] . [7] . CD spectra were recorded at increasing IRIM/calf thymus DNA ratio (r= 0.0, 0.01, 0.1, 1.0) after mixing on a Jasco J600 dichrograph operating at room temperature, interfaced with a PC, and analyzed through the standard Jasco software package.
Cytotoxicity measurements were carried out on the A2780 ovarian carcinoma cell line, both sensitive and resistant to cisplatin (A2780/S and A2780/R) following the Sulphorhodamine-B (SRB) procedure [8] , and data analyzed through standard methods. Cells were exposed to the cytotoxic agent for 72 hours.
The activity of IRIM on the B 16 melanoma, MCF7 breast cancer and TS adenocarcinoma tumor cell lines was also analyzed, upon treatment 24 or 72 hours long. Cell growth of samples treated with increasing concentrations of IRIM -10 M, 10" M and 104M-was monitored in comparison to controls through the microculture tetrazolium test (MTT) [9] or SRB method [8] . 
RESULTS

Interactions of lRIM with calf thymus DNA
The interactions of IRIM with calf thymus DNA in vitro was first analyzed by visible spectroscopy.
As previously reported [6] , IRIM is soluble in a physiological buffer and gives rise to a characteristic absorption spectrum in the visible. Notably, the visible spectrum of IRIM does not change over a period of several hours, at room temperature, implying that the metal chromophore is relatively stable under physiological conditions [6] . 
DISCUSSION
Metal complexes other than platinum are today actively investigated as potential cytotostatic and antitumor drugs. In this frame, much work has been devoted to the analysis of ruthenium(III) complexes that showed in some cases promising biological and pharmacological profiles. A ruthenium(III) complex-NAMI A-is presently undergoing phase clinical trials. Structural analogues of ruthenium(III) complexes may be prepared by using rhodium(III) or iridium(III) as the central metal/on. We are exploiting iridium(III) analogues of known antitumor ruthenium(III) complexes as novel antitumor agents; the aim is to define the chemical and biological consequences resulting from the replacement of the ruthenium(III) center with the more inert iridium(III) center.
In this paper we report on the biological behaviour of IRIM, trans bisimidazole tetrachloro iridate(III), compared to ICR. Specifically two aspects of the pharmacological behaviour of IRIM have been stressed: i) the interaction with DNA; ii) the cytotoxic effects on a number of human tumor cell lines. i) The interaction with DNA DNA was selected since it represents a major target for platinum(II) antitumor compounds and is the probable target for several other antitumor metal complexes. 
